guys you're never gonna believe this

Certains matheux te disent "à homéomorphisme près" mais ne sauraient pas te construire un (1) homéomorphisme concrètement si leur vie en dépendait

every known prime number is of the form n.

Sensory neurons in triple-negative breast cancer secrete CGRP that activate fibroblasts to build a collagen fence that blocks out T cells. Targeting the nervous system may be a good way to tear down the fence and give immune cells access to tumors. The authors conclude: "CGRP

While he was writing ULYSSES, Joyce told his friend Frank Budgen that he’d spent eight hours working on a single sentence. The sentence: “The heaventree of stars hung with humid, nightblue fruit.”

💬 Perspective: Bayesian methodology supports efficient, flexible clinical trial designs; FDA guidance encourages prespecification and sensitivity analysis of priors. Frank Harrell David Spiegelhalter ja.ma/47hHTyb

Grok, what is Abraxane? What is Abraxane used for? How does it work? Who discovered and developed it? Who manufactures and markets Abraxane?

Frank Harrell Elmir Omerovic To claim that Bayesian methods are more likely to compromise research integrity than frequentist ones is a textbook example of what Andrew Gelman et al. calls: “straining on the gnat of the prior distribution while swallowing the camel that is the likelihood”: statmodeling.stat.columbia.edu/2023/04/27/str…

1/n Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD Our KRAS G12D degrader study is now published in the New England Journal of Medicine NEJM nejm.org/doi/full/10.10… A new way to target KRAS G12D - one of the most common oncogenic

A method of drawing infinitely many touching circles Credit: Matt Henderson

The TIGIT catastrophe‼️ 30 agents 220 trials ~50,000 patients >$3B+ invested 0 approvals. This is herding in drug development. In BMJ Oncol we examine why it happens, the hidden costs, and what needs to change. It’s already happening again in ADCs... 🔗:bmjoncology.bmj.com/content/5/1/e0…

Just 1,500 feet (457 m) from the Artemis II launch, we deployed our special high-resolution, slow-motion camera to record the blast-off in jaw-dropping detail at 2,000 frames per second. Find out how we did it: on.natgeo.com/0BXGmi

Make new friends, but keep the old. A new photo captures the Moon's near side on the right (the side we see from Earth, identifiable by its dark splotches) and its far side on the left. The Artemis II crew are the first to see the far side with human eyes.

RevMed just doubled overall survival in pancreatic cancer by using CypA-targeting molecular glues to potently drug oncogenic KRAS-ON, long deemed untouchable. One funny thing is that probably the most fundamental insight for daraxonrasib sits in a PNAS paper that's been cited

New promising phase 1 study for lung cancer NEJM * Zongertinib in HER2-Mutant NSCLC -ORR 76% (tumor shrinkage in most patients) -PFS 14.4 mo (disease control) -Brain mets: 47% response ✅

Almanya’daki Sprengel Müzesi’nde sergilenen sıra dışı bir kinetik enstalasyon: Havada sallanan bir şamandıra, Atlantik Okyanusu’ndaki gerçek ikiziyle eşzamanlı hareket ediyor ve dalgalar üzerindeki salınımını birebir taklit ediyor.

New compound from Revolution Medicines RM-055 disclosed at #AACR26 They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models.

It's time for all drug developers to reconsider heavily relying on Wuxi to synthesize their proprietary compounds How $ERAS obtained ERAS-0015 from Wuxi>Joyo>$ERAS should be a case study $RVMD used Wuxi to synthesize their very early pan-RAS compounds, and guess what? Wuxi

Excited to share our discovery of a new programmable RNA-guided DNA-targeting system hiding inside bacteriophages that predates CRISPR. We call it VIPR (Viral Interference Programmable Repeat), and it uses an entirely new logic to find its targets. Thread + link below.